Showing results (301-310 of 679) with videos related to

Sort By:
Pageof 68
American Journal of Hematology|February 18, 2014
Long-term outcome of monoclonal (type 1) cryoglobulinemiaAntoine Néel, François Perrin, Olivier Decaux, et al.
Haematologica|October 14, 2021
Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysisMarcelo Capra, Thomas Martin, Philippe Moreau, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 8, 2015
Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III TrialKatja Weisel, Meletios Dimopoulos, Kevin W Song, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|March 6, 2012
Dosimetry results suggest feasibility of radioimmunotherapy using anti-CD138 (B-B4) antibody in multiple myeloma patientsCaroline Rousseau, Ludovic Ferrer, Stéphane Supiot, et al.
Plos One|January 4, 2017
Haplotypes of the HLA-G 3' Untranslated Region Respond to Endogenous Factors of HLA-G+ and HLA-G- Cell Lines DifferentiallyIsabelle Poras, Layale Yaghi, Gustavo Martelli-Palomino, et al.
Blood|October 5, 2016
Rational targeted therapies to overcome microenvironment-dependent expansion of mantle cell lymphomaDavid Chiron, Céline Bellanger, Antonin Papin, et al.
Hemasphere|July 17, 2025
Current and future role of carfilzomib-based quadruplet combinations as therapy for newly diagnosed multiple myelomaOla Landgren, Noa Biran, Elizabeth K O'Donnell, et al.
Blood Cancer Journal|July 2, 2026
Expression profile of CASSIOPEIA patients refines prognostic value of MRD negativity in multiple myelomaFlorence Magrangeas, Catherine Guérin-Charbonnel, Victor Bessonneau-Gaborit, et al.
Applied Health Economics and Health Policy|February 26, 2013
Cost effectiveness of pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous stem cell transplantation in patients with lymphoma and myeloma: an economic evaluation of the PALM TrialLionel Perrier, Anne Lefranc, David Pérol, et al.
Journal of Clinical Medicine|February 9, 2020
Are the Immune Properties of Mesenchymal Stem Cells from Wharton's Jelly Maintained during Chondrogenic Differentiation?Charlotte Voisin, Ghislaine Cauchois, Loïc Reppel, et al.
Pageof 68